Uncoupling CD4þ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Arianna Draghi
  • Mario Presti
  • Agnete W.P. Jensen
  • Christopher A. Chamberlain
  • Benedetta Albieri
  • Anne Christine K. Rasmussen
  • Mads H. Andersen
  • Michael D. Crowther
  • Svane, Inge Marie
  • Marco Donia

Purpose: Impaired MHCI-presentation and insensitivity to interaction. Around 40% of melanomas constitutively express immune effector molecules are common features of immune MHC Class II molecules; hence, melanomas with or without checkpoint blockade (ICB)-resistant tumors and can be, respecnatural constitutive MHC Class II expression (MHCIIconstþ or tively, associated with loss of b2 microglobulin (B2M) or impaired MHCIIconst-) were used. IFNg signaling. Patients with ICB-resistant tumors can respond to Results: CD4þ TIL-mediated cytotoxicity was not affected by alternative immunotherapies, such as infusion of autologous B2M loss but was dependent on the expression of CIITA. tumor-infiltrating lymphocytes (TIL). CD4þ T cells can exert MHCIIconstþ melanomas were killed by tumor-specific CD4þ TILs cytotoxic functions against tumor cells; however, it is unclear even in the absence of IFNg-mediated MHCII upregulation, where-whether CD4þ T-cell responses can be exploited to improve the as IFNg was necessary for CD4þ TIL-mediated cytotoxicity against clinical outcomes of patients affected by ICB-resistant tumors. MHCIIconst- melanomas. Notably, although tumor-specific CD4þ Experimental Design: Here, we exploited CRISPR (clustered TILs did not kill JAK1KO MHCIIconst- melanomas even after IFNg regularly interspaced short palindromic repeats)/Cas9 gene edit-stimulation, sensitivity to CD4þ TIL-mediated cytotoxicity was ing to reproduce immune-resistant tumor phenotypes via gene maintained by JAK1KO MHCIIconstþ melanomas. knockout (KO). To determine the role of cytotoxic CD4þ TILs Conclusions: In conclusion, our data indicate that exploiting in ICB-resistant tumors, we investigated CD4þ TIL-mediated tumor-specific cytotoxic CD4þ TILs could help overcome resistance cytotoxicity in matched pairs of TILs and autologous melanoma to ICB mediated by IFNg-signaling loss in MHCIIconstþ melanomas. cell lines, used as a model of patient-specific immune-tumor See related commentary by Betof Warner and Luke, p. 3829

OriginalsprogEngelsk
TidsskriftClinical Cancer Research
Vol/bind29
Udgave nummer19
Sider (fra-til)3937-3947
Antal sider11
ISSN1078-0432
DOI
StatusUdgivet - 1 okt. 2023

Bibliografisk note

Funding Information:
A. Draghi reports grants from The Danish Cancer Society, Lundbeck Foundation, Danish National Board of Health, Independent Research Fund Denmark, Herlev and Gentofte Hospital Research Council, and University of Copenhagen during the conduct of the study. M.H. Andersen reports grants and personal fees from IO

Funding Information:
The authors wish to thank all the patients who donated the samples used in this study and the funding sources who generously supported this research (research grant R204-A12535, The Danish Cancer Society, to M. Donia; research grant R307–2018– 3636, Lundbeck Foundation, to M. Donia; grant 8045–00067B, Independent Research Fund Denmark, to M. Donia; grant number 05–0400–18/05–0400–50 "Empowering Cancer Immunotherapy in Denmark," Danish National Board of Health, to I.M. Svane; the Herlev and Gentofte Hospital Research Council under Clinician-Scientist Grant, to M. Donia; grant “IKMs 2021 Forskningspulje,” University of Copenhagen, to M. Donia). Dr. M. Hansen (CCIT-DK, Denmark) is acknowledged for technical assistance with the flow cytometry set-up. Dr. K. Mølgaard Jensen (CCIT-DK, Denmark) is acknowledged for assistance in performing Mycoplasma testing. Dr. É. Bourbeau (Copenhagen, Denmark) is acknowledged for assistance in statistical analyses. Marta Velasco Santiago (CCIT-DK, Denmark) is acknowledged for assistance in selected experiments. Aimilia Schina (CCIT-DK, Denmark) is acknowledged for bioinformatic assistance.

Publisher Copyright:
2023 American Association for Cancer Research.

ID: 389960438